Terminal / Weight Loss

Cagrilintide

Phase 3

aka AM833

Long-acting amylin analog, usually run alongside semaglutide as CagriSema.

Mechanism

An amylin receptor agonist that drives satiety and slows gastric emptying, a different lever than GLP-1. Stack it with semaglutide (that combo is CagriSema) and the two mechanisms add up.

Regulatory & Safety Status

Investigational (Novo Nordisk), late-stage trials. Not approved yet.

Research

2026Naunyn-Schmiedeberg's archives of pharmacology

Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials

2026Physiology & behavior

Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding

2026Pharmacological research

Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs

2026Annals of medicine and surgery (2012)

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo

2024PubMed

Latest cagrilintide research

Related Compounds

Weight Loss

Semaglutide

Approved

Approved GLP-1 agonist. The drug that kicked off the whole weight-loss gold rush.

Weight Loss

Retatrutide

Phase 3

Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.